MAPS Act

MAPS Act (Mapping America’s Pharmaceutical Supply Act) would strengthen federal coordination to identify health and national security risks in drug supply chains. It establishes an Essential Medicines List (EML) that includes medicines and ingredients critical for public health, and for national security and military readiness. The act requires regular updates to the EML, and a comprehensive risk assessment of the supply chains for the medicines on that list, covering starting materials, foreign suppliers, domestic manufacturing capacity, cybersecurity risks, and policy gaps. In parallel, it directs HHS to map and monitor pharmaceutical supply chains using data analytics to visualize vulnerabilities and improve information sharing across federal agencies and with industry. The bill also mandates the Department of Defense to report biannually on drugs connected to Chinese-origin materials or manufacturing. Overall, the MAPS Act seeks to improve transparency, resilience, and coordination to prevent shortages and mitigate national security risks.